Jafron (SZSE:300529) reports robust 2024 growth and future plans

Jafron Biomedical (SZSE:300529) has released a series of announcements highlighting a successful 2024 fiscal year and its strategic direction for 2025. The company reported a 39.27% year-over-year increase in operating income, reaching CNY2.677 billion, with net profits attributable to shareholders rising by 87.91% to CNY820 million. The company's board has approved a profit distribution plan of CNY8.00 per 10 shares. Factoring in a share repurchase completed in September 2024, the aggregate returns to investors totaled CNY1.119 billion, representing 120.33% of the annual net profit.